Literature DB >> 10935989

Human herpesvirus 6 infection after living related liver transplantation.

T Yoshikawa1, M Ihira, K Suzuki, S Suga, K Iida, Y Saito, K Asonuma, K Tanaka, Y Asano.   

Abstract

The aim of the study was to investigate human herpesvirus-6 (HHV-6) infection after liver transplantation from living related donors, and to evaluate the reliability of the presence of HHV-6 DNA in plasma by the polymerase chain reaction (PCR) for monitoring active HHV-6 infection. EDTA peripheral blood was collected from 47 donor and recipient (16 males and 31 females, age 1-320 months) pairs at the time of transplantation and biweekly from these recipients after transplantation until 2 months after operation. Isolation of HHV-6 and serological assays were carried out to evaluate active HHV-6 infection in this study. The presence of the viral DNA in plasma was tested by nested PCR. Four clinical events, such as unexplained fever, thrombocytopenia, rejection, and central nervous system (CNS) involvement, were evaluated for clinical features of the virus infection. Risk factors for the virus activity after liver transplantation were also examined. HHV-6 activity was detected in 23 (49%) of the 47 recipients approximately 2-4 weeks after transplantation. All 9 isolates were HHV-6 variant B. The presence of the viral DNA in plasma correlated well with virus isolation and serology (P < 0.01). Only unexplained fever was associated statistically with HHV-6 activity after liver transplantation (P < 0. 01). If the recipient was seronegative to HHV-6 before transplantation, the recipient was more likely to develop the active virus infection after liver transplantation (P = 0.11). HHV-6 activity occurred in one-half of the recipients approximately 2-4 weeks after liver transplantation, and there was a close association between HHV-6 activity and unexplained fever following transplantation. Detection of the viral DNA in plasma by PCR is useful for monitoring active HHV-6 infection in these patients. Seronegative recipients were more likely to have evidence of active HHV-6 infection after liver transplantation. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935989

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Detection of human herpesvirus 7 DNA by loop-mediated isothermal amplification.

Authors:  Tetsushi Yoshikawa; Masaru Ihira; Shiho Akimoto; Chie Usui; Fumi Miyake; Sadao Suga; Yoshihiko Enomoto; Ryota Suzuki; Yukihiro Nishiyama; Yoshizo Asano
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Rapid diagnosis of human herpesvirus 6 infection by a novel DNA amplification method, loop-mediated isothermal amplification.

Authors:  Masaru Ihira; Tetsushi Yoshikawa; Yoshihiko Enomoto; Shiho Akimoto; Masahiro Ohashi; Sadao Suga; Naoko Nishimura; Takao Ozaki; Yukihiro Nishiyama; Tsugunori Notomi; Yoshinori Ohta; Yoshizo Asano
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 4.  Human herpesvirus 6 and human herpesvirus 7: emerging pathogens in transplant patients.

Authors:  Duncan A Clark
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

5.  Novel marmoset (Callithrix jacchus) model of human Herpesvirus 6A and 6B infections: immunologic, virologic and radiologic characterization.

Authors:  Emily Leibovitch; Jillian E Wohler; Sheila M Cummings Macri; Kelsey Motanic; Erin Harberts; María I Gaitán; Pietro Maggi; Mary Ellis; Susan Westmoreland; Afonso Silva; Daniel S Reich; Steven Jacobson
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

6.  Coinfection of human herpesviruses 6A (HHV-6A) and HHV-6B as demonstrated by novel digital droplet PCR assay.

Authors:  Emily C Leibovitch; Giovanna S Brunetto; Breanna Caruso; Kaylan Fenton; Joan Ohayon; Daniel S Reich; Steven Jacobson
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.